Dostarlimab-gxly Receives Full FDA Approval in dMMR Endometrial Cancer


Patients with mismatch repair deficient recurrent/advanced endometrial cancer can receive treatment with dostarlimab-gxly following its full approval by the FDA.

The FDA has granted full approval to dostarlimab-gxly (Jemperli) as treatment for patients with mismatch repair deficient (dMMR) recurrent/advanced endometrial cancer, according to a press release from the FDA.1

The regular approval was based on data from the phase 1 GARNET trial (NCT02715284), which included a total of 141 patients with dMMR recurrent/advanced endometrial cancer who had progressed following a platinum-containing treatment.

Dostarlimab yielded a confirmed overall response rate of 45.4% (95% CI, 37.0%-54.0%) including a 15.6% complete response rate and 29.8% partial response rate. The median duration of response was not reached, and 85.9% and 54.7% of patients had responses lasting 12 months or more and 24 months or more, respectively.

Frequent adverse effects (AEs) included fatigue, anemia, rash, nausea, diarrhea, constipation, and vomiting. Immune-mediated AEs included pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin adverse reactions.

The FDA granted accelerated approval to dostarlimab for dMMR recurrent or advanced endometrial cancer in April 2021, which was also supported by data from the GARNET trial.2


  1. FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer. News release. FDA. February 9, 2023. Accessed February 9, 2023.
  2. FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker. News release. FDA. April 21, 2021. Accessed February 9, 2023.
Related Videos
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content